Form 4: Blueprint Medicines Executive Receives Stock Options and Restricted Stock Units

Percy H. Carter, Chief Scientific Officer of Blueprint Medicines, reports the acquisition of stock options and restricted stock units.

Summary

• Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines, filed a Form 4 on March 4, 2025.
• The report details changes in beneficial ownership of Blueprint Medicines Corp [BPMC] securities.
• Carter acquired 11,000 restricted stock units on March 1, 2025, under the Issuer's 2024 Stock Incentive Plan.
• Carter also acquired 22,000 stock options (Right to Buy) with an exercise price of $96.57 on March 1, 2025.
• These options vest monthly starting April 1, 2025, over a period of 48 months.
• Following these transactions, Carter directly owns 60,395 shares of common stock and 22,000 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting transactions. The sentiment is slightly positive as it indicates continued investment in the company by a key executive.

Positives

• The grant of stock options and restricted stock units to the Chief Scientific Officer could be seen as an incentive to align his interests with those of the shareholders.
• The vesting schedule of the options (monthly over 48 months) encourages long-term commitment from the executive.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options suggests a long-term commitment from the executive.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to incentivize and retain key executives. The specific terms of the grant (vesting schedule, exercise price) are company-specific and reflect their compensation strategy.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used to align management's interests with shareholder value.
• Vesting schedules, like the 1/48th monthly vesting described, are common to encourage long-term retention.
• Comparing the size of the grant (22,000 options) and the exercise price ($96.57) to similar companies (e.g., other mid-cap biotechs) would provide a benchmark for assessing the competitiveness of the compensation package.

Stakeholder Impact

• The grant of stock options and restricted stock units could positively impact shareholders by incentivizing the Chief Scientific Officer to drive company performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates